Last $13.70 USD
Change Today +0.28 / 2.09%
Volume 740.2K
INFI On Other Exchanges
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/9/13 - $18.35
52 Week Low
05/7/14 - $8.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company has strategic collaboration with AbbVie Inc. to develop and commercialize duvelisib (IPI-145) in oncology. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

180 Employees
Last Reported Date: 02/25/14

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $378.8K
President of Research & Development
Total Annual Compensation: $465.8K
Chief Scientific Officer
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. Enters into a First Amendment to Facility Agreement with Deerfield Management Company, L.P

Infinity Pharmaceuticals, Inc. entered into a first amendment to facility agreement with affiliates of Deerfield Management Company, L.P. to amend that certain facility agreement dated as of February 24, 2014 by and among the company and the lenders. Under the first amendment, the company and the lenders have agreed to reduce the maximum principal amount that the company may draw down under the credit facility established under the facility agreement, subject to the terms and conditions set forth therein, from $100,000,000 to $50,000,000. Accordingly, under the first amendment, the fee owed by the company on February 27, 2015 or upon the earlier termination or acceleration of the credit facility has been reduced from 3% of the then-undrawn portion of the previous $100,000,000 commitment to 3% of the then-undrawn portion of the revised $50,000,000 commitment. To date, the company has not drawn down any portion of funds available to it under the credit facility.

AbbVie Inc., Infinity Pharmaceuticals, Inc. - Special Call

To discuss the Infinity Pharmaceuticals, Inc.'s strategic collaboration with AbbVie Inc

Infinity Pharmaceuticals, Inc. and AbbVie Inc. Announce Global Strategic Collaboration to Develop and Commercialize duvelisib (IPI-145) in Oncology

Infinity Pharmaceuticals, Inc. and AbbVie Inc. announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMO(TM), a Phase 2 study in patients with iNHL, and DUO(TM), a Phase 3 study in patients with CLL. Under the terms of the agreement, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib. In the U.S., the companies will jointly commercialize duvelisib and will share equally in any potential profits. Outside the U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity is eligible to receive tiered double-digit royalties on net product sales. As part of the strategic collaboration, the companies will share responsibility for the conduct of specific trials specified within an agreed-upon global development plan, with each company leading the development of certain trials within the plan. The agreement includes plans to launch multiple Phase 2 and Phase 3 studies of duvelisib in hematologic malignancies over the next several years.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $13.70 USD +0.28

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INFI.
View Industry Companies

Industry Analysis


Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at